• PRE-TEST QUESTIONNAIRE

    Sunday, September 7th, 2025 | Palm Beach, Florida

  • Clinical Update for Non-Cystic Fibrosis Bronchiectasis: Strategies to Manage Exacerbations and Lung Function
    Supported by an independent education grant from Insmed

  • 1. Which of the following should be considerations when evaluating a patient for bronchiectasis?*
  • 2. Which of the following medications should be considered for treatment of this patients slow respiratory decline?*

  • Update on Long-Acting Nebulizers for Guideline-Based Maintenance Treatments for Patients with COPD
    Supported by an independent education grant from Viatris Specialty LLC

  • Therapeutic Update on COPD with Type 2 Inflammation
    Supported by an independent education grant from GSK

  • 3. What proportion of patients who experience a severe COPD exacerbation are re-hospitalized within 30 days?*
  • 4. Which of the following should be the initial pharmacologic treatment plan for a patient diagnosed with COPD who is in GOLD group E?*
  • 5. In the Phase 3 MATINEE trial, treatment with Mepolizumab was associated with reductions in COPD exacerbations of:*

  • Thank you! Please press submit to enter your information. 

  • Should be Empty: